In a report released on November 14, Michael Okunewitch from Maxim Group maintained a Buy rating on BioRestorative Therapies, with a price target of $8.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Okunewitch has given his Buy rating due to a combination of factors that highlight BioRestorative Therapies’ promising prospects. The company’s ongoing clinical programs, particularly the BRTX-100 cell therapy for chronic lumbar disc disease (CLDD), are showing encouraging signs. The trial, which is nearing completion, has demonstrated significant improvements in pain and function among participants, suggesting a potential therapeutic benefit. Additionally, BioRestorative has plans to expand into cervical spinal pain treatment, further broadening its clinical scope.
Moreover, the company’s financial position appears stable, with sufficient capital to sustain operations through mid-2026, bolstered by recent equity financing. The appointment of a seasoned leader in the biocosmeceuticals sector also positions BioRestorative to capitalize on growth opportunities in the skin care and med-spa industries. These strategic moves, combined with the promising clinical data, underpin Okunewitch’s optimistic outlook and Buy rating for the stock.
Okunewitch covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Lineage Therap, and Ocugen. According to TipRanks, Okunewitch has an average return of -5.0% and a 37.50% success rate on recommended stocks.